Cidara's CD388 Phase 3 ANCHOR trial for flu prevention is recruiting, enrollment up to 10,000

This week's update covers a single registered trial for CD388, sponsored by Cidara Therapeutics Inc., described in the record as a subsidiary of Merck & Co., Inc.

• CD388 (MK-1406), Phase 3, influenza prevention: The trial, known as "ANCHOR," is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of MK-1406 (CD388) administered as a single dose via 3 subcutaneous injections¹ in participants who may be more vulnerable to complications from influenza because of their age, health conditions, or weakened immune systems¹. The study is listed as recruiting, with an estimated enrollment of 10000 participants¹ and a primary completion date estimated for 2027-06-30.